Home > Dermatology > AAD 2018 > Late-breakers > Behcet’s syndrome and hidradenitis suppurativa

Behcet’s syndrome and hidradenitis suppurativa

Presented By
Dr Yusuf Yazici, New York University School of Medicine, USA; Prof. Evangelos Giamarellos-Bourboulis, University of Athens Medical School, Greece
Conference
AAD 2018
Trial
RELIEF
Apremilast effective in Behcet's Syndrome The oral phosphodiesterase (PDE)4 inhibitor apremilast displayed a significant effect on ulcers and ulcer pain associated with Behcet´s syndrome in the RELIEF trial [16]. Behcet's syndrome is a rare, chronic, multi-system inflammatory disorder characterised by oral and genital ulcers, skin lesions, uveitis, arthritis, with vascular, central nervous system, and gastrointestinal involvement. A key symptom occurring in nearly all patients is painful recurrent oral ulcers that can be disabling and have a substantial effect on QoL: there are currently no effective treatment options for them. The oral PDE4 inhibitor apremilast modulates inflammatory mediators and has demonstrated efficacy in a Phase 2 Behcet's syndrome study. These preliminary data were the reason for a Phase 3 trial with apremilast. In the RELIEF study, a total of 207 patients were randomised to apremilast (30 mg twice daily) or placebo. A...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on